Overview

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the highest dose of ON 01910.Na that can be safely given as an intravenous infusion over 24 hours once a week in a 3-week cycle to patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Onconova Therapeutics, Inc.
Treatments:
Glycine
ON 01910